AstraZeneca PLC Expands R&D in China to Boost Drug Discovery; Pharmaron LLC Will Add Hundreds of Scientists to Astra Team

Published: Oct 15, 2012

AstraZeneca Plc (AZN), which has the worst-performing stock this year among Europe’s biggest drugmakers, will work with a research company in China to speed discovery of new medicines.

The partnership with Beijing-based Pharmaron will add “a few hundred” scientists to AstraZeneca’s 300-strong team in China, Martin Mackay, AstraZeneca’s president of global R&D, said in an interview in Shanghai. The move marks the London- based company’s biggest expansion in research in the world’s fastest-growing pharmaceuticals market.

Back to news